Compare ATGL & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATGL | AMRN |
|---|---|---|
| Founded | 2017 | 1989 |
| Country | Hong Kong | Ireland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 286.4M | 339.8M |
| IPO Year | 2023 | 1998 |
| Metric | ATGL | AMRN |
|---|---|---|
| Price | $16.55 | $14.32 |
| Analyst Decision | | Strong Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 2.4K | ★ 83.9K |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $181,104,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 39.22 |
| 52 Week Low | $9.01 | $0.35 |
| 52 Week High | $50.00 | $20.90 |
| Indicator | ATGL | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 41.63 | 46.83 |
| Support Level | $15.35 | $13.65 |
| Resistance Level | $20.58 | $16.94 |
| Average True Range (ATR) | 1.67 | 0.75 |
| MACD | 0.04 | -0.11 |
| Stochastic Oscillator | 20.49 | 42.17 |
Alpha Technology Group Ltd operates through its subsidiaries, which are established cloud-based IT solution service providers in Hong Kong. Its Operating Subsidiaries utilize its analytic skills, programming skills, artificial intelligence technologies and technological know-how to provide comprehensive solutions designed to optimize the business performance of customers, meet various industry-specific operational challenges of customers and create new business opportunities for customers. The Operating Subsidiaries provide services for customers from a variety of industries, including consulting, real estate, architectural design, carpark management, electronic payment services, logistics, investments, retail, textiles, wholesale and distribution, etc.
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.